545 related articles for article (PubMed ID: 31555576)
1. Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
Del Giudice I; Raponi S; Della Starza I; De Propris MS; Cavalli M; De Novi LA; Cappelli LV; Ilari C; Cafforio L; Guarini A; Foà R
Front Oncol; 2019; 9():689. PubMed ID: 31555576
[TBL] [Abstract][Full Text] [Related]
2. Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin MD; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CU; Kater AP
J Clin Oncol; 2023 Jul; 41(21):3689-3699. PubMed ID: 37279408
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy.
Thompson PA; Srivastava J; Peterson C; Strati P; Jorgensen JL; Hether T; Keating MJ; O'Brien SM; Ferrajoli A; Burger JA; Estrov Z; Jain N; Wierda WG
Blood; 2019 Nov; 134(22):1951-1959. PubMed ID: 31537528
[TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
Uchiyama T; Yokoyama A; Aoki S
J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
[TBL] [Abstract][Full Text] [Related]
6. Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ; van der Klift MY; Kolijn PM; Davi F; Kavelaars FG; de Jonge E; Robrecht S; Assmann JLJC; van der Straten L; Ritgen M; Westerweel PE; Fischer K; Goede V; Hallek M; Levin MD; Langerak AW
Blood; 2023 Feb; 141(5):519-528. PubMed ID: 36084320
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation.
Böttcher S; Ritgen M; Pott C; Brüggemann M; Raff T; Stilgenbauer S; Döhner H; Dreger P; Kneba M
Leukemia; 2004 Oct; 18(10):1637-45. PubMed ID: 15343348
[TBL] [Abstract][Full Text] [Related]
8. MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VHJ; van Dongen JJM; Kneba M
Methods Mol Biol; 2019; 1956():199-228. PubMed ID: 30779036
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL.
Scarfò L; Heltai S; Albi E; Scarano E; Schiattone L; Farina L; Moia R; Deodato M; Ferrario A; Motta M; Reda G; Sancetta R; Coscia M; Rivela P; Laurenti L; Varettoni M; Perotta E; Capasso A; Ranghetti P; Colia M; Ghia P
Blood; 2022 Dec; 140(22):2348-2357. PubMed ID: 35921541
[TBL] [Abstract][Full Text] [Related]
10. Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
Thompson PA; Wierda WG
Blood; 2016 Jan; 127(3):279-86. PubMed ID: 26576865
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in chronic lymphocytic leukaemia.
García Vela JA; García Marco JA
Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.
Uhrmacher S; Erdfelder F; Kreuzer KA
Adv Hematol; 2010; 2010():. PubMed ID: 20886004
[TBL] [Abstract][Full Text] [Related]
13. Minimal Residual Disease in Chronic Lymphocytic Leukemia in the Era of Novel Agents: A Review.
Thompson M; Brander D; Nabhan C; Mato A
JAMA Oncol; 2018 Mar; 4(3):394-400. PubMed ID: 28750119
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Fürstenau M; Giza A; Weiss J; Kleinert F; Robrecht S; Franzen F; Stumpf J; Langerbeins P; Al-Sawaf O; Simon F; Fink AM; Schneider C; Tausch E; Schetelig J; Dreger P; Böttcher S; Fischer K; Kreuzer KA; Ritgen M; Schilhabel A; Brüggemann M; Stilgenbauer S; Eichhorst B; Hallek M; Cramer P
Blood; 2024 Apr; ():. PubMed ID: 38620072
[TBL] [Abstract][Full Text] [Related]
15. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.
Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ
J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712
[TBL] [Abstract][Full Text] [Related]
16. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
García-Marco JA; Jiménez JL; Recasens V; Zarzoso MF; González-Barca E; De Marcos NS; Ramírez MJ; Parraga FJP; Yañez L; De La Serna Torroba J; Malo MDG; Ariznavarreta GD; Persona EP; Guinaldo MAR; De Paz Arias R; Llanos EB; Jarque I; Valle MDCF; Tatay AC; De Oteyza JP; Martin EMD; Fernández IP; Martinez RM; Costa MAA; Champ D; Suarez JG; Díaz MG; Ferrer S; Carbonell F; García-Vela JA;
Haematologica; 2019 Nov; 104(11):2249-2257. PubMed ID: 30890600
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease in chronic lymphocytic leukemia.
Benintende G; Pozzo F; Innocenti I; Autore F; Fresa A; D'Arena G; Gattei V; Lurenti L
Front Oncol; 2023; 13():1112616. PubMed ID: 36865804
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
[TBL] [Abstract][Full Text] [Related]
19. Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.
Allan JN; Flinn IW; Siddiqi T; Ghia P; Tam CS; Kipps TJ; Barr PM; Elinder Camburn A; Tedeschi A; Badoux XC; Jacobs R; Kuss BJ; Trentin L; Zhou C; Szoke A; Abbazio C; Wierda WG
Clin Cancer Res; 2023 Jul; 29(14):2593-2601. PubMed ID: 37282671
[TBL] [Abstract][Full Text] [Related]
20. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR; Starza ID; Messina M; Reda G; Trentin L; Coscia M; Sportoletti P; Orsucci L; Arena V; Casaluci GM; Marasca R; Murru R; Laurenti L; Ilariucci F; Stelitano C; Mannina D; Massaia M; Rigolin GM; Scarfò L; Marchetti M; Levato L; Tani M; Arcari A; Musuraca G; Deodato M; Galieni P; Patrizi VB; Gottardi D; Liberati AM; Giordano A; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; De Propris MS; Nanni M; Del Giudice I; Guarini A; Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R
Haematologica; 2023 Aug; 108(8):2091-2100. PubMed ID: 36632738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
